La Jolla enters agreement with Stanford University La Jolla Pharmaceutical announced that it has signed an option agreement with Leland Stanford Junior University that will add proprietary technology to the company’s programs. The option agreement with Stanford allows La Jolla to test the technology potentially adding product opportunities to La Jolla’s pipeline. La Jolla is currently testing novel oral formulations using the technology in an animal model of Non-alcoholic Steatohepatitis. If successful, these product candidates will add to the company’s pipeline.
News For LJPC From The Last 14 Days
Check below for free stories on LJPC the last two weeks.